Page 39 - pest-POSTEN nr 1, 2017

®
MYCAMINE (micafungin)
Sikkerhetsinformasjon: Prøver for soppkultivering og andre relevante laboratorietester (inkl. histopatologi) bør tas før behandling,
for å isolere og identifisere årsaksorganisme(r). Behandlingen kan startes før dyrkingsresultaterne og andre laboratorietester er
kjent. Behandlingen bør gis etter nøye nytte-risikovurdering, spesielt ved alvorlig leversvikt eller kroniske leversykdommer. 1 HØJER 01/2017/MYC-176790-NO

MYCAMINE
®

is in your toolbox!

Make it your choice for your patients
with invasive candidiasis

Mycamine has proven clinical efficacy against a range of Candida species including C.albicans
l
and potentially more difficult-to-treat species, such as C.glabrata and C.parasilosis 2,3
l Generally well tolerated in a broad range of patients, including those with severe and life-
threatening underlying conditions 4
l Grade A recommendation in the ESCMID guidelines for treatment of invasive candidiasis in
adults and children 5,6

1. Mycamine SPC 06-2016 (sek. 4.2).
2. Pappas PG, Rotstein CMF, Betts RF et al. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive
Candidiasis. Clinical Infectious Diseases 2007; 45: 883–93.
3. Shorr AF, Wu C, Kothari S et al. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and
Candida krusei. Journal of Antimicrobial Chemotherapy 2011; 66: 375-80.
4. Cornely O, Pappas P, Young J et al. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opinion on
Drug Safety 2011; 10: 171-83.
5. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic
adult patients. Clinical Microbiology and Infection 2012; 18 Suppl 7: 19–37.
6. Hope WW, Castagnola E, Groll AH et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and
management of invasive infections in neonates and children caused by Candida spp. Clinical Microbiology and Infection 2012; 18: 38–52.

ASTELLAS PHARMA | Solbråveien 47 | 1383 Asker | Tlf.: 66 76 46 00 | kontakt.no@astellas.com | www.astellas.no